<turbo-stream action="append" target="audio_clips_list"><template>
    <hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8868433-rwd-at-scale-how-verana-health-and-cota-are-shaping-the-future-of-clinical-development"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43508123/75x75/c 75w, https://audioboom.com/i/43508123/150x150/c 150w, https://audioboom.com/i/43508123/300x300/c 300w, https://audioboom.com/i/43508123/600x600/c 600w, https://audioboom.com/i/43508123/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #c0c0c0; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43508123/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
RWD at Scale: How Verana Health and COTA Are Shaping the Future of Clinical Development
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this episode of the Applied Clinical Trials Podcast, C.K. Wang, MD, chief medical officer at COTA; and Sujay Jadhav, CEO of Verana Health, discuss how their organizations’ merger is advancing the use of real-world data to inform trial design, patient recruitment, and regulatory decision-making.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
21m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1772479778" data-format="short_date">Mar 02</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
21m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8867428-act-brief-bayesian-designs-gain-ground-data-priorities-take-shape-and-rare-disease-strategy-ex"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Bayesian Designs Gain Ground, Data Priorities Take Shape, and Rare Disease Strategy Expands
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we explore how Bayesian trial designs are gaining traction in rare disease research, what priorities clinical operations leaders should focus on in 2026, and how rare disease science is shaping broader drug development strategies.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1772449200" data-format="short_date">Mar 02</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8866630-act-brief-sites-advance-ai-adoption-cross-functional-alignment-moves-earlier-and-phase-i-strat"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Sites Advance AI Adoption, Cross-Functional Alignment Moves Earlier, and Phase I Strategy Evolves
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we explore how sites are taking the lead on AI adoption to strengthen feasibility and enrollment, why earlier cross-functional alignment is critical in data-driven trials, and how Phase I strategy is shifting toward quantitative evidence generation.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1772190000" data-format="short_date">Feb 27</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8866270-act-brief-data-fragmentation-risks-rise-outsourcing-models-evolve-and-fda-pathways-face-pressure"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Data Fragmentation Risks Rise, Outsourcing Models Evolve, and FDA Pathways Face Pressure
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how fragmented data collection continues to challenge trial quality, how hybrid outsourcing and AI are reshaping execution strategies, and why calls are growing for a risk-based FDA pathway for early-stage studies.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1772103600" data-format="short_date">Feb 26</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8865577-act-brief-esource-standardization-advances-digital-protocols-gain-momentum-and-rare-disease-tr"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: eSource Standardization Advances, Digital Protocols Gain Momentum, and Rare Disease Trial Risks Intensify
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how protocol-driven eSource is reshaping data capture at sites, how digital protocols and data sharing are redefining trial execution, and how a Duchenne study termination highlights growing operational risks in rare disease development.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1772017200" data-format="short_date">Feb 25</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8864978-act-brief-site-data-quality-takes-priority-merck-expands-ai-discovery-efforts-and-gilead-advan"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Site Data Quality Takes Priority, Merck Expands AI Discovery Efforts, and Gilead Advances Cell Therapy Strategy
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo Clinic are scaling AI-driven discovery, and how Gilead’s latest acquisition strengthens its position in cell therapy for multiple myeloma.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771930800" data-format="short_date">Feb 24</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8864785-act-brief-evinova-expands-ai-partnerships-ctpm-role-evolves-and-fda-pressure-builds-on-glp-1-m"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Evinova Expands AI Partnerships, CTPM Role Evolves, and FDA Pressure Builds on GLP-1 Market
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how Evinova is scaling AI-driven clinical development through industry collaboration, how the clinical trial project manager role is evolving amid growing complexity, and how FDA scrutiny of compounded GLP-1s could reshape market dynamics.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771864184" data-format="short_date">Feb 23</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8863455-act-brief-scope-highlights-operational-discipline-ai-adoption-accelerates-execution-and-fda-re"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: SCOPE Highlights Operational Discipline, AI Adoption Accelerates Execution, and FDA Rethinks Evidence Standards
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how SCOPE 2026 reinforced the link between speed and strategy, how AI adoption is driving real-world efficiency gains, and how FDA’s evolving evidence standards could reshape approval pathways.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771585200" data-format="short_date">Feb 20</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8862957-act-brief-predictive-analytics-advance-collaborative-data-standards-scale-and-moderna-s-flu-va"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Predictive Analytics Advance, Collaborative Data Standards Scale, and Moderna’s Flu Vaccine Review Moves Forward
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how predictive analytics are shaping portfolio decisions, how industry collaboration is scaling digital data standards, and how FDA review of an mRNA flu vaccine candidate is back on track.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771498800" data-format="short_date">Feb 19</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8862408-act-brief-ai-enables-real-time-trial-oversight-provider-engagement-strengthens-recruitment-and"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI Enables Real-Time Trial Oversight, Provider Engagement Strengthens Recruitment, and HHS Leadership Restructures Operations
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how AI is enabling continuous trial monitoring and faster site decisions, how provider participation influences recruitment in pragmatic trials, and how leadership restructuring at HHS may shape health policy execution.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771412400" data-format="short_date">Feb 18</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8861952-act-brief-ai-moves-into-implementation-digital-measurement-adoption-accelerates-and-global-tri"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI Moves Into Implementation, Digital Measurement Adoption Accelerates, and Global Trial Competition Intensifies
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how AI is shifting from pilot programs into daily development workflows, how a new adoption platform is helping sponsors integrate digital measurement tools, and how global competition and data-driven site selection are reshaping clinical trial activity.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771326000" data-format="short_date">Feb 17</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8861785-act-brief-esource-moves-toward-ai-enabled-validation-outsourcing-models-shift-toward-flexibilit"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: eSource Moves Toward AI-Enabled Validation, Outsourcing Models Shift Toward Flexibility, and Robust Trial Design Becomes Mission Critical
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we explore how eSource adoption is advancing with AI-enabled validation and interoperability, examine how flexible outsourcing models are helping sponsors balance control and efficiency, and highlight why adaptive, simulation-driven trial design is becoming essential to improving study success.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771251946" data-format="short_date">Feb 16</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8860954-act-brief-regional-risk-variability-emerges-patient-experience-drives-retention-and-digital-en"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Regional Risk Variability Emerges, Patient Experience Drives Retention, and Digital Endpoints Scale in Oncology
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine new data on regional variation in clinical trial risk, why patient experience must move from intent to execution, and how digital endpoints are advancing efficiency and regulatory alignment in oncology trials.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1770992467" data-format="short_date">Feb 13</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8860443-act-brief-real-world-data-connectivity-expands-ai-supports-smarter-data-capture-and-diversity"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Real-World Data Connectivity Expands, AI Supports Smarter Data Capture, and Diversity Strategies Refocus at SCOPE
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we cover a new real-world data collaboration aimed at scalable interoperability, how AI fits into modern data capture and quality oversight, and what leaders say must change to move diversity efforts forward in clinical trials.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1770906510" data-format="short_date">Feb 12</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8859633-act-brief-ai-scales-trial-design-esg-becomes-a-readiness-test-and-sites-push-back-on-payment-p"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI Scales Trial Design, ESG Becomes a Readiness Test, and Sites Push Back on Payment Practices
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we cover how AI is being deployed to optimize global trial design, why ESG performance is emerging as a core vendor qualification signal, and how sites are becoming more selective as payment practices come under scrutiny.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1770807600" data-format="short_date">Feb 11</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8859088-act-brief-purpose-meets-operational-focus-acceleration-shifts-upstream-and-ai-delivers-near-te"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Purpose Meets Operational Focus, Acceleration Shifts Upstream, and AI Delivers Near-Term Impact
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we highlight how purpose-driven efficiency is reshaping clinical development priorities, where leaders see the greatest opportunity for accelerating trial timelines, and how artificial intelligence is already influencing decisions across the R&amp;D lifecycle.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1770721200" data-format="short_date">Feb 10</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8854362-act-brief-fda-capacity-strains-timelines-sponsors-rethink-site-support-and-regulators-align-on-ai"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how reduced FDA capacity is extending regulatory timelines, why sponsors are rethinking operating models to reduce site burden in 2026, and how the FDA and EMA are aligning around guiding principles for artificial intelligence in drug development.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1769770800" data-format="short_date">Jan 30</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8854189-act-brief-rwe-refines-trial-design-oncology-cro-scale-expands-and-feasibility-pressures-persist"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: RWE Refines Trial Design, Oncology CRO Scale Expands, and Feasibility Pressures Persist
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at how real-world evidence is reshaping trial design rather than replacing trials, what Worldwide Clinical Trials’ acquisition of Catalyst Clinical Research signals for oncology-focused CRO models, and new data showing feasibility and enrollment challenges remain stubborn across global trials.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1769697851" data-format="short_date">Jan 29</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8850689-act-brief-esg-moves-into-vendor-oversight-rwe-faces-governance-hurdles-and-roche-advances-obes"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: ESG Moves Into Vendor Oversight, RWE Faces Governance Hurdles, and Roche Advances Obesity Pipeline
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine why ESG efforts in clinical development are shifting into vendor oversight, what data and governance barriers still limit broader use of de-identified RWE in submissions, and new Phase II obesity data from Roche as its program moves toward Phase III.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1769598000" data-format="short_date">Jan 28</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8846115-act-brief-decentralized-innovation-faces-reality-rwe-finds-its-lane-and-clinical-ops-reset-for"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Decentralized Innovation Faces Reality, RWE Finds Its Lane, and Clinical Ops Reset for 2026
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we explore why decentralized trial innovations struggle to scale without better change management, where real-world evidence most realistically complements traditional trials, and how efficiency, AI, and platformization are expected to reshape clinical operations in 2026.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1769511600" data-format="short_date">Jan 27</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8844278-act-brief-de-identified-data-expands-trial-design-global-production-normalizes-and-fda-updates"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: De-Identified Data Expands Trial Design, Global Production Normalizes, and FDA Updates Quality Framework
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how large de-identified datasets are reshaping trial design and site strategy, why global pharmaceutical production is expected to cool after a tariff-driven surge, and what FDA’s new M4Q(R2) draft guidance means for quality submissions.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1769425200" data-format="short_date">Jan 26</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8838719-act-brief-de-identified-rwe-gains-ground-hhs-funding-stabilizes-research-and-u-s-finalizes-wh"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: De-Identified RWE Gains Ground, HHS Funding Stabilizes Research, and U.S. Finalizes WHO Exit
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at how FDA policy is accelerating the use of de-identified real-world evidence in clinical development, why a new bipartisan funding package could stabilize federal research agencies, and how the US withdrawal from the World Health Organization reshapes global health coordination.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1769166000" data-format="short_date">Jan 23</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8837815-act-brief-global-trials-scale-up-site-centric-startup-gains-focus-and-pfizer-expands-vaccine-p"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Global Trials Scale Up, Site-Centric Startup Gains Focus, and Pfizer Expands Vaccine Partnerships
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging markets, why site-centric practices are becoming critical to faster study activation, and how a new Pfizer–Novavax agreement reflects shifting vaccine development strategies.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1769079600" data-format="short_date">Jan 22</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8837288-act-brief-life-sciences-hold-the-line-on-dei-startup-timelines-stretch-further-and-regulators"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Life Sciences Hold the Line on DEI, Startup Timelines Stretch Further, and Regulators Align on AI Governance
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
 In today’s ACT Brief, we examine why life sciences companies are maintaining DEI commitments amid political pressure, what’s driving longer site activation timelines and how sponsors can reverse the trend, and how FDA and EMA are aligning on principles for AI use in drug development.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1768993200" data-format="short_date">Jan 21</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8836806-act-brief-signal-durability-redefines-rbqm-ai-targets-startup-friction-and-cdmos-advance-patie"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Signal Durability Redefines RBQM, AI Targets Startup Friction, and CDMOs Advance Patient-Centric Formulation
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management, how AI can reduce startup delays without burdening sites, and how patient-centric drug design is reshaping the CDMO landscape.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1768950000" data-format="short_date">Jan 20</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8835964-act-brief-closing-gender-gaps-in-parkinson-s-research-startup-communication-breakdowns-and-a-n"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Closing Gender Gaps in Parkinson’s Research, Startup Communication Breakdowns, and a New White House Healthcare Plan
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why communication failures continue to delay study startup, and how a new White House healthcare plan aims to reduce drug and insurance costs.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1768820400" data-format="short_date">Jan 19</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8834974-act-brief-ai-extends-trial-registries-contract-bottlenecks-delay-activation-and-data-integrati"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI Extends Trial Registries, Contract Bottlenecks Delay Activation, and Data Integration Pushes Integrated Care
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at how AI is reshaping clinical trial registries into discovery tools, why contract and budget negotiations remain the biggest drag on site activation timelines, and how integrated data platforms are closing gaps across payer, provider, and patient care.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1768561200" data-format="short_date">Jan 16</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8834509-act-brief-moving-beyond-ai-pilots-fda-advances-bayesian-trials-and-sites-strained-by-trial-design"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Moving Beyond AI Pilots, FDA Advances Bayesian Trials, and Sites Strained by Trial Design
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine what will separate sponsors that scale AI beyond pilots in 2026, break down the FDA’s new draft guidance on Bayesian statistical methods in clinical trials, and explore how poor planning and trial design continue to place operational strain on research sites.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1768474800" data-format="short_date">Jan 15</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8833885-act-brief-community-sites-prove-readiness-platformization-reshapes-clinical-ops-and-ai-targets"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Community Sites Prove Readiness, Platformization Reshapes Clinical Ops, and AI Targets Precision Care at JPM
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at how community research sites can stay competitive under efficiency pressure, why 2026 is shaping up as a turning point for platform-based clinical operations, and how AI is being positioned to better match patients to therapies.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1768388400" data-format="short_date">Jan 14</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8829101-act-brief-community-sites-compete-on-readiness-coa-licensing-bottlenecks-slow-start-up-and-ai"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how community research sites can stay competitive under rising efficiency pressures, why clinical outcome assessment licensing remains a drag on trial start-up, and what’s holding back AI-driven pharmacovigilance at scale.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1768302000" data-format="short_date">Jan 13</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8828249-act-brief-trial-competition-slows-ai-gains-rethinking-patient-level-safety-decisions-and-what"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Trial Competition Slows AI Gains, Rethinking Patient-Level Safety Decisions, and What Separates Real AI Platforms in Clinical Trials
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at how growing trial competition is undermining AI-driven efficiency gains, why pharmacovigilance is shifting toward patient-level causal reasoning, and what AI life sciences companies must demonstrate to stand out in a crowded market.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1768215600" data-format="short_date">Jan 12</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8827778-act-brief-recalibrating-trial-efficiency-and-access-verana-cota-merge-to-expand-rwe-scale-and"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Recalibrating Trial Efficiency and Access, Verana-COTA Merge to Expand RWE Scale, and FDA Rejects Hetlioz Jet Lag Indication
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we hear how sponsors may redefine efficiency to protect patient access in 2026, review Verana Health’s merger with COTA to expand real-world evidence capabilities, and examine FDA’s latest decision on Vanda’s Hetlioz for jet lag disorder.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1767956400" data-format="short_date">Jan 09</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8827341-act-brief-eu-comparator-drug-sourcing-pressures-ai-expands-its-role-in-oncology-trials-and-ret"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: EU Comparator Drug Sourcing Pressures, AI Expands Its Role in Oncology Trials, and Rethinking AI Value in Clinical Development
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven oncology collaboration between BostonGene and AstraZeneca, and explore why AI life sciences companies are being pushed to prove real operational value beyond hype.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1767870000" data-format="short_date">Jan 08</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8826858-act-brief-rethinking-representation-in-cancer-trials-positive-phase-iib-sle-data-and-a-major-o"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson &amp; Johnson’s positive Phase IIb results for nipocalimab in systemic lupus erythematosus, and break down a new multibillion-dollar research and licensing agreement between Nimbus Therapeutics and Eli Lilly targeting oral obesity treatments.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1767783600" data-format="short_date">Jan 07</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8826430-act-brief-reframing-site-initiation-readiness-operational-execution-as-competitive-advantage-a"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Reframing Site Initiation Readiness, Operational Execution as Competitive Advantage, and a Historic Motion Sickness Approval
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated readiness, examine how AI and decentralized infrastructure are reshaping clinical operations strategy, and review FDA’s approval of the first new pharmacologic motion sickness treatment in more than four decades.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1767697200" data-format="short_date">Jan 06</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8826272-act-brief-persistent-barriers-to-cancer-trial-participation-clarifying-irt-data-ownership-and"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Persistent Barriers to Cancer Trial Participation, Clarifying IRT Data Ownership, and Clinical Trial Opportunities in Sub-Saharan Africa
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine persistent barriers limiting cancer trial participation and emerging approaches to address them, outline new guidance clarifying investigator versus sponsor ownership of IRT data, and review evidence highlighting sub-Saharan Africa’s capacity to support controlled clinical trials.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1767628096" data-format="short_date">Jan 05</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8825553-act-brief-support-services-and-cancer-trial-access-2025-s-most-watched-act-video-interviews-an"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Support Services and Cancer Trial Access, 2025’s Most-Watched ACT Video Interviews, and FDA Approval of Narsoplimab
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine new data from the American Cancer Society on how transportation and lodging support affect cancer trial participation, review the most-viewed Applied Clinical Trials video interviews of 2025, and break down key trial results supporting the FDA approval of narsoplimab for transplant-associated thrombotic microangiopathy.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
3m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1767366300" data-format="short_date">Jan 02</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
3m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8823354-act-brief-fda-approval-of-oral-wegovy-2025-s-most-read-act-coverage-and-data-quality-as-the-fo"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: FDA Approval of Oral Wegovy, 2025’s Most-Read ACT Coverage, and Data Quality as the Foundation for AI
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read Applied Clinical Trials articles of 2025, and examine why data quality remains critical to enabling AI in clinical trials.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1766587148" data-format="short_date">Dec 24, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8822963-act-brief-ai-enabled-workflow-automation-subcutaneous-lunsumio-velo-approval-and-pan-kras-earl"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI-Enabled Workflow Automation, Subcutaneous Lunsumio VELO Approval, and Pan-KRAS Early-Stage Development
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at how AI-enabled workflows can automate existing site processes, review the FDA approval of subcutaneous Lunsumio VELO for relapsed or refractory follicular lymphoma, and examine early clinical development activity for a pan-KRAS inhibitor licensed by AstraZeneca.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1766502045" data-format="short_date">Dec 23, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8822524-act-brief-building-a-digital-thread-in-life-sciences-cro-sourcing-decisions-and-site-burden-an"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Building a Digital Thread in Life Sciences, CRO Sourcing Decisions and Site Burden, and Lilly’s Oral GLP-1 Phase III Results
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor sourcing decisions may affect site experience and study execution, and report on topline Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1766418615" data-format="short_date">Dec 22, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8820958-act-brief-neutral-tech-adoption-at-sites-scaling-unstructured-data-for-esource-and-novo-nordis"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Neutral Tech Adoption at Sites, Scaling Unstructured Data for eSource, and Novo Nordisk’s CagriSema NDA
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, review new research on integrating unstructured health data to scale eSource-enabled trials, and cover Novo Nordisk’s NDA submission for its fixed-dose amylin–GLP-1 obesity therapy, CagriSema.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1766142000" data-format="short_date">Dec 19, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8820527-act-brief-rethinking-site-support-in-2026-gsk-s-new-severe-asthma-approval-and-priority-review"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s twice-yearly biologic for severe asthma, and examine a national priority voucher granted for a new multiple myeloma treatment combination.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1766052000" data-format="short_date">Dec 18, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8820337-act-brief-patient-preferences-in-remote-trials-sanofi-s-neurology-and-immunology-deals-and-ai"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Patient Preferences in Remote Trials, Sanofi’s Neurology and Immunology Deals, and AI-Driven Biomarkers in Oncology
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine new survey data revealing what patients value most in remote clinical trials, break down Sanofi’s latest partnerships aimed at advancing Alzheimer’s and autoimmune therapies, and look at how AI-powered digital pathology is being integrated into oncology research through a new biopharma collaboration.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1765986996" data-format="short_date">Dec 17, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8819674-act-brief-ai-enabled-end-to-end-trials-new-phase-iii-data-in-hiv-and-a-first-line-shift-in-her"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI-Enabled End-to-End Trials, New Phase III Data in HIV, and a First-Line Shift in HER2-Positive Breast Cancer
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to end, review new Phase III data supporting Gilead’s investigational HIV regimen, and examine an FDA approval that reshapes first-line treatment for HER2-positive metastatic breast cancer.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1765896638" data-format="short_date">Dec 16, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8819223-act-brief-training-community-oncology-sites-digital-tools-for-patient-centric-trials-and-new-p"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Training Community Oncology Sites, Digital Tools for Patient-Centric Trials, and New Phase III Momentum in Obesity R&amp;D
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer centers, explore McKinsey’s view on how digital tools can make trials more patient-centric and geographically inclusive, and review new Phase III results that could reshape obesity and osteoarthritis treatment.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1765816947" data-format="short_date">Dec 15, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8818447-act-brief-ai-enabled-coa-migration-expanding-trial-footprints-into-routine-care-and-new-fda-ap"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI-Enabled COA Migration, Expanding Trial Footprints into Routine Care, and New FDA Approval in Myasthenia Gravis
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we examine new data on how AI is improving the accuracy and speed of COA localization, break down McKinsey’s perspective on why trials must expand beyond AMCs and into routine care settings, and highlight the FDA’s latest approval of a targeted biologic for generalized myasthenia gravis.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1765561723" data-format="short_date">Dec 12, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8817781-act-brief-ai-s-impact-on-trial-timelines-new-strategies-in-obesity-r-d-and-why-patient-support"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI’s Impact on Trial Timelines, New Strategies in Obesity R&amp;D, and Why Patient Support Needs a Clinical Backbone
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we highlight new insights from McKinsey on where AI can meaningfully accelerate clinical development, break down the emerging design and regulatory forces reshaping obesity drug development, and examine why human-centered clinical guidance is becoming essential within an increasingly fragmented pharmacy system.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1765472044" data-format="short_date">Dec 11, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8817252-act-brief-new-car-t-trial-requirements-pfizer-advances-oral-glp-1-strategy-and-kisqali-shows-d"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: New CAR-T Trial Requirements, Pfizer Advances Oral GLP-1 Strategy, and Kisqali Shows Durable Long-Term Control
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we break down FDA’s new superiority requirement reshaping CAR-T development, examine Pfizer’s global move into oral small-molecule GLP-1 therapy, and highlight new MONALEESA findings that reinforce long-term disease control with Kisqali.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1765385766" data-format="short_date">Dec 10, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8816728-act-brief-governance-driven-ecoa-acceleration-site-operations-innovation-and-new-momentum-for"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: Governance-Driven eCOA Acceleration, Site Operations Innovation, and New Momentum for Earlier CAR-T
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we explore how stronger vendor–sponsor governance is speeding eCOA study startup, hear from AMR Clinical on the biggest opportunities to advance site operations and collaboration, and highlight new long-term data supporting earlier use of Carvykti in relapsed or refractory multiple myeloma.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1765300624" data-format="short_date">Dec 09, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8816072-act-brief-ai-driven-repurposing-advances-gcp-adoption-challenges-and-new-car-t-milestone"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43250260/75x75/c 75w, https://audioboom.com/i/43250260/150x150/c 150w, https://audioboom.com/i/43250260/300x300/c 300w, https://audioboom.com/i/43250260/600x600/c 600w, https://audioboom.com/i/43250260/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43250260/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
ACT Brief: AI-Driven Repurposing Advances, GCP Adoption Challenges, and New CAR-T Milestone
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s ACT Brief, we look at how AI and in-silico methods are reshaping drug repurposing, why staggered ICH GCP rollouts are creating new operational pressure points, and the FDA’s latest CAR-T approval expanding treatment options in B-cell malignancies.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1765205154" data-format="short_date">Dec 08, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>

</template></turbo-stream>
  <turbo-stream action="replace" target="turbo_pagination"><template><turbo-frame loading="lazy" id="turbo_pagination" src="/channels/5120065-applied-clinical-trials.turbo_stream?page=3"><div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div class="visually-hidden">
<a href="/channels/5120065-applied-clinical-trials?page=3">next page</a>
</div>
</turbo-frame></template></turbo-stream>
